Amylase inhibitors

Amylase inhibitors/Drug Interactions:

  • Antidiabetic agentsAntidiabetic agents: In humans, amylase inhibitors may reduce postprandial glucose, C-peptide, and gastric inhibitory polypeptide (19). Thus, there is a potential for interactions between amylase inhibitors and hypoglycemic agents. Amylase-inhibiting drugs, such as acarbose and voglibose, are often used for diabetes (22).
  • Weight loss medicationsWeight loss medications: Preliminary evidence suggests that amylase inhibitors may increase weight loss over dieting alone (4). Thus, there is a potential for interaction between amylase inhibitors and weight loss agents.

    • Amylase inhibitors/Herb/Supplement Interactions:

  • Garcinia cambogiaGarcinia cambogia: In humans, a combination of amylase inhibitor, inulin, and Garcinia cambogia extract increased weight loss compared with placebo (23).
  • GuarGuar: Guar is a source of soluble and bound amylase inhibitors (14). Thus, there is a potential for interaction if guar and amylase inhibitors are taken at the same time.
  • HypoglycemicsHypoglycemics: In humans, amylase inhibitors may reduce postprandial glucose, C-peptide, and gastric inhibitory polypeptide (19). Thus, there is a potential for interaction between amylase inhibitors and hypoglycemic agents.
  • InulinInulin: In humans, a combination of amylase inhibitor, inulin, and Garcinia cambogia extract increased weight loss compared with placebo (23).
  • Rosmarinic acidRosmarinic acid: Herbal extracts containing rosmarinic acid have been shown to inhibit amylase activity in vitro (24). Theoretically, amylase inhibitors and other plant constituents may have additive effects as well.
  • Weight loss agentsWeight loss agents: Preliminary evidence suggests that amylase inhibitors may increase weight loss over dieting alone (4). Thus, there is a potential for interaction between amylase inhibitors and weight loss agents.

    • Amylase inhibitors/Food Interactions:

  • Diabetic dietDiabetic diet: In humans, amylase inhibitors may reduce postprandial glucose, C-peptide, and gastric inhibitory polypeptide (19). Thus, there is a potential for interaction between amylase inhibitors and a diet designed for diabetic patients.
  • Dietary carbohydratesDietary carbohydrates: In humans, powdered amylase inhibitor decreased amylase activity by greater than 96% and increased malabsorption of wheat starch (25). Thus, use of amylase inhibitor may decrease absorption of dietary carbohydrates.
  • Dietary fiberDietary fiber: Dietary fiber is a source of soluble and bound amylase inhibitors in guar and other dietary roughage (14). Thus, there is a potential for interaction if dietary fiber and amylase inhibitors are taken at the same time.
  • LegumesLegumes: Legumes are a source of amylase inhibitors (12; 13; 14; 15). Thus, there is a potential for interaction if dietary fiber and amylase inhibitors are taken at the same time.
  • Weight reducing dietWeight reducing diet: Preliminary evidence suggests that amylase inhibitors may increase weight loss over dieting alone (4). Thus, there is a potential for interaction between amylase inhibitors and a diet designed for weight reduction.

    • Amylase inhibitors/Lab Interactions:

  • C-peptideC-peptide: In humans, amylase inhibitors may reduce postprandial C-peptide (19; 3).
  • Fecal mineralsFecal minerals: In rats, amylase inhibitor increased fecal zinc and copper (26).
  • Gastric inhibitory polypeptideGastric inhibitory polypeptide: In humans, amylase inhibitors may reduce postprandial gastric inhibitory polypeptide (19; 27; 3).
  • InsulinInsulin: In humans, an increase in postprandial insulin was abolished after the use of amylase inhibitors (3). In rats, the use of amylase inhibitors with a starch load had no effect on postprandial insulin levels (20).
  • Peptide YYPeptide YY: In humans, wheat-derived amylase inhibitor increased levels of peptide YY in blood (27).
  • Serum glucoseSerum glucose: In humans, amylase inhibitors may reduce postprandial glucose (19; 27; 3). In rats, the use of amylase inhibitors with a starch load decreased postprandial glycemia (20).